[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-non-small-cell-lung-cancer-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-non-small-cell-lung-cancer-nsclc":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,80,103,131,159,187,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644072","phase-2-a-phase-ii-study-of-ak146d1-in-combination-with-ak112-in-advanced-non-small-cell-lung-cancer-100644072",false,"NCT07669779","A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Be able to understand and voluntarily sign the written informed consent form.\n2. Aged of ≥ 18 years and ≤75 years.\n3. ECOG PS 0 or 1.\n4. The expected lifespan is ≥3 months.\n5. Patients with histologically or cytologically confirmed locally advanced (Stage IIIB\u002FIIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who are not eligible for curative surgical resection and cannot receive definitive concurrent or sequential chemoradiotherapy.\n6. At least one measurable non-brain lesion according to RECIST v1.1.\n7. Have sufficient organ function.\n8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential. Agree to use medically accepted methods of contraception.\n\nExclusion Criteria:\n\n1. NSCLC mixed with a component of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma.\n2. Having other active malignancies within 3 years.\n3. Currently participating in another interventional clinical study.\n4. Presence of active metastases to the central nervous system. For patients with asymptomatic brain metastasis or stable symptoms after treatment can be included.\n5. Having received any treatment targeting Trop2 or Nectin4.\n6. Prior chemotherapy or antibody-drug conjugate (ADC) therapy targeting topoisomerase I inhibitors.\n7. Receipt of systemic anti-tumor therapy (including chemotherapy, immunotherapy, biological agents, etc.) within 4 weeks (or 5 half-lives of the drug, whichever is longer) prior to the first dose.\n8. Toxicity of previous antineoplastic therapy has not resolved to NCI CTCAE 6.0 grade 1 or lower.\n9. Subjects with clinically significant cardiovascular or cerebrovascular diseases or risks.\n10. Subjects with active autoimmune diseases requiring systemic treatment within 2 years.\n11. Receipt of systemic anti-infective therapy within 2 weeks prior to the first dose.\n12. Known to be positive for HIV and other infections.\n13. Previous history of severe hypersensitivity reactions.\n14. Live attenuated vaccines were received within 4 weeks.\n15. Subjects with a history of mental illness and incapacitated or limited capacity.\n16. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.","ALL","18 Years","75 Years",{"count":20,"type":21},348,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.",[27],"Advanced Non Small Cell Lung Cancer (NSCLC)","NOT_YET_RECRUITING","2026-06-21",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":21},"2026-06-30",{"date":36,"type":21},"2029-05-30",{"name":38,"class":39},"Akeso","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":40},"100642296","impact-of-liquid-biopsy-on-the-therapeutic-pathway-for-lung-cancer-advancing-the-molecular-characterization-of-patients-with-advanced-lung-adenocarcinoma-by-integrating-liquid-biopsy-into-the-early-stages-of-the-diagnostic-and-therapeutic-pathway-100642296","NCT07649629","Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway","Impatto Della Biopsia Liquida Sul Percorso Terapeutico Del Tumore al Polmone: Anticipare la Caratterizzazione Molecolare Dei Pazienti Con Adenocarcinoma Del Polmone in Stadio Avanzato Integrando la Biopsia Liquida Nella Fase Iniziale Del Percorso Diagnostico-terapeutico","INNOVA-LUNG","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Radiological suspicion of locally advanced lung cancer not amenable to locoregional treatment or metastatic lung cancer (stage III-IV).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.\n* Tissue biopsy and\u002For cytological sampling planned but not yet performed, or already performed without an available histopathological diagnosis of non-small cell lung cancer (NSCLC).\n* Written informed consent for study participation and personal data processing obtained before any study-specific procedure.\n\nExclusion Criteria:\n\n* Previous or current history of non-small cell lung cancer (NSCLC).\n* Histopathological diagnosis of NSCLC already available following tissue biopsy.\n* Eligibility for surgical removal of tumor tissue.\n* Ongoing or previous systemic oncological treatment for lung cancer.",{"count":50,"type":21},70,"OBSERVATIONAL","This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).\n\nLiquid biopsy is a minimally invasive blood test that can detect tumor-related genetic alterations in circulating nucleic acids. The study will evaluate whether this approach can provide molecular information more rapidly than standard tissue-based testing and how closely the results obtained from blood samples match those obtained from tumor tissue.\n\nApproximately 70 adult patients with radiological evidence of locally advanced or metastatic lung cancer will be enrolled. Participants will undergo a blood draw for liquid biopsy and will continue to follow the standard diagnostic pathway, including tissue biopsy or cytological sampling when indicated.\n\nThe results generated within the study are intended for research purposes and will not replace standard diagnostic procedures or independently determine treatment decisions. The findings will be used to identify practical and methodological issues and to support the design of future clinical studies on the plasma-first approach.",[54],"Advanced Non-small Cell Lung Cancer (NSCLC)",[56,57,58,59,60,61,62,63,64,65,66,67,68],"Lung Cancer","Liquid biopsy","Plasma-first approach","Non-small cell lung cancer","NSCLC","ctDNA","ctRNA","NGS","Molecular profiling","Tumor fraction","Actionable genomic alterations","Targeted therapy","Biomarkers","RECRUITING","2026-06-10",{"date":72,"type":32},"2026-06-16",{"date":74,"type":32},"2025-09-01",{"date":76,"type":21},"2027-03-01",{"name":78,"class":79},"Regina Elena Cancer Institute","OTHER",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100638296","phase-1-amt-116-in-combination-with-ivosidan-in-patients-with-lung-cancer-100638296","NCT07590531","AMT-116 in Combination With Ivosidan in Patients With Lung Cancer","An Open-label, Multicenter Phase Ib\u002FII Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivosimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent for this trial.\n2. At the time of screening, aged ≥18 years and ≤75 years.\n3. Histologically or cytologically confirmed locally advanced (Stage IIIB\u002FIII C) or metastatic (Stage IV) NSCLC that is not amenable to complete surgical resection and cannot be treated with curative concurrent or sequential chemoradiotherapy (according to the 8th edition of the International Union Against Cancer and the American Joint Committee on Cancer TNM staging for lung cancer).\n4. Stage Ib: Locally advanced\u002Fmetastatic NSCLC; both subjects who have previously received systemic therapy and those who have not may be enrolled;\n\n   Phase II: Each cohort must meet the following requirements:\n\n   Cohort 1: Histologically or cytologically diagnosed with non-squamous NSCLC, EGFR wild-type, and ALK fusion-negative.\n\n   Co-hort 2: Histologically or cytologically diagnosed with squamous-cell NSCLC, known to be EGFR wild-type and ALK fusion gene-negative.\n\n   Co-hort 3: Histologically or cytologically diagnosed with non-squamous NSCLC and harboring an EGFR mutation.\n5. Subjects must have at least one measurable lesion (as defined by RECIST 1.1 criteria).\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Expected survival of ≥12 weeks.\n8. Subjects' laboratory test results must meet the requirements.\n9. Women of child-bearing potential (WCBP) must consent to the use of two effective contraceptive methods during the study treatment period and for at least 12 weeks after the final administration of IMP\n10. Women of child-bearing potential (WCBP) must have a negative serum pregnancy test within seven days preceding the initial administration of the investigational medicinal product (IMP).\n11. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 12 weeks after the last dose of the IMP.\n12. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.\n\nKey Exclusion Criteria:\n\n1. Histopathological evidence of small cell lung cancer.\n2. For Cohort 1 and Cohort 2 of Phase II, patients must not have non-small cell lung cancer with known EGFR-sensitive mutations, ALK fusions, BRAF V600E mutations, ROS1 fusions, MET exon 14 skipping mutations, NTRK fusions, or RET fusions.\n3. Prior treatment with any CD44v9-targeted therapy or an antibody-drug conjugate (ADC) based on a topoisomerase I inhibitor as the toxin.\n4. Received the following treatments or medications prior to the start of the study:\n\n   i. Systemic anticancer therapy, including chemotherapy and biologics, within 3 weeks prior to the first dose; hormonal anticancer therapy or small-molecule targeted therapy within 2 weeks prior to the first dose; or Chinese herbal medicines or proprietary Chinese herbal preparations with anticancer indications within 2 weeks prior to the first dose. Received nonspecific immunomodulatory therapy (e.g., interleukins, interferons, thymosin, tumor necrosis factor, etc.) within 2 weeks prior to the first dose.\n\n   ii. Received a live or attenuated vaccine within 4 weeks prior to the first dose.\n\n   iii. Received radiation therapy within 3 weeks prior to the first dose. Palliative radiation therapy administered for symptom control at least 2 weeks prior to the first dose is permitted.\n5. Received systemic immunosuppressive therapy (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to the first dose.\n6. Adverse reactions from prior treatment have not yet resolved to Grade 1 or less.\n7. Subjects who have experienced an immune-related adverse event (irAE) requiring permanent discontinuation of treatment, or a Grade 3 or higher irAE, or a cardiac, neurological, or ocular irAE of any grade (including Grade 2 immune-related pneumonia, but excluding Grade 3 hypothyroidism that can be controlled with hormone replacement therapy).\n8. Known symptomatic brain metastases or other central nervous system (CNS) metastases, or brain metastases or other CNS metastases that the investigator deems to require treatment but have not been treated. Subjects with asymptomatic brain metastases or a history of brain metastases that have been stable for ≥2 weeks prior to the first dose may be eligible for this study, provided they meet all of the following criteria: no metastases to the meninges, midbrain, pons, cerebellum, medulla oblongata, or spinal cord, or spinal cord compression; discontinuation of hormonal therapy for more than 2 weeks prior to the first dose; imaging studies performed within at least 4 weeks show no evidence of new or enlarged brain metastases.\n9. History of malignancy other than the enrollment diagnosis within 5 years prior to the first administration of the study drug.\n10. Underwent major surgery within 4 weeks prior to the first administration of the study drug, or has not fully recovered from surgery; or sustained a major traumatic injury within 4 weeks prior to the first administration; or is scheduled to undergo surgery during the anticipated duration of study participation or within 4 weeks after the last administration.\n11. History of interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid therapy; current ILD\u002Fpneumonia; suspected ILD\u002Fpneumonia (e.g., idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, idiopathic pneumonia, etc.); or other pulmonary diseases that significantly impair lung function at baseline.\n12. History of active autoimmune disease or a history of autoimmune disease requiring systemic treatment within the past 2 years.\n13. Current or past history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).\n14. History of hypertensive crisis or hypertensive encephalopathy.\n15. Subjects with severe coagulation disorders or other evidence of significant bleeding risk.\n16. Uncontrolled pleural effusion or ascites requiring repeated drainage within 4 weeks prior to the first dose.\n17. Active infection treated with systemic antimicrobial therapy within 2 weeks prior to the first dose. Severe infection occurring within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia.\n18. History of abdominal fistula, tracheoesophageal fistula, or female genital fistula (e.g., vesicovaginal fistula, ureterovaginal fistula, and vesicovaginal fistula), gastrointestinal perforation, or abdominal abscess; or if the investigator considers the subject to have risk factors for gastrointestinal obstruction. If the fistula or perforation has been treated by resection or repair, and the investigator assesses that the condition has fully resolved, the subject may be enrolled.\n19. The subject has uncontrolled comorbidities, including but not limited to poorly controlled hypertension or diabetes, psychiatric disorders, or conditions that may limit study compliance, or other comorbidities or conditions that the investigator believes may affect study judgment or interfere with the completion of study procedures and follow-up examinations.\n20. Known immunosuppressive disease or human immunodeficiency virus (HIV) infection.\n21. Patients who are positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis C virus (HCV) antibodies at screening are ineligible for enrollment, unless hepatitis B virus (HBV) DNA levels and HCV RNA testing clearly rule out active infection requiring antiviral treatment for hepatitis B or C (HBV DNA ≥ 1000 cps\u002FmL or 200 IU\u002FmL).\n22. Known active tuberculosis (TB); suspected active tuberculosis must be ruled out by clinical examination.\n23. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, excluding corneal transplantation.\n24. Known immediate-type or delayed-type hypersensitivity to the study drug, a history of allergic reactions, or allergy to any component of the study drug or excipients.\n25. Pregnancy (positive β-human chorionic gonadotropin \\[β-hCG\\] test) and lactating women.\n26. The subject is unwilling or unable to comply with the protocol.\n27. The subject requires the use of a potent CYP3A4 inhibitor within one week prior to dosing or during the study.\n28. Any other disease, metabolic disorder, physical examination findings, or clinical laboratory results that raise suspicion of contraindications to the study drug, or that may affect the subject's safety, the interpretation of study results, or place the subject at high risk of complications.\n\n    \\-",{"count":88,"type":21},118,[90,24],"PHASE1","The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.",[54],"2026-05-10",{"date":95,"type":32},"2026-05-15",{"date":97,"type":21},"2026-05-01",{"date":99,"type":21},"2027-12-31",{"name":101,"class":39},"Multitude Therapeutics Inc.",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100640301","phase-2-clinical-effects-of-alpha-lipoic-acid-in-advanced-nsclc-100640301","NCT07574684","Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC","The Effect of Alpha Lipoic Acid on the Clinical Outcome of Advanced Non-Small Cell Lung Cancer Patients","ALA \u002FNSCLC","Inclusion Criteria:\n\n* Adult patients (\\>18 years old).\n* Non-respectable Stage III and IV NSCLC.\n* Patients ECOG PS of 0-2.\n* With no-actionable or unknown driver mutation\n* Planned to receive platinum doublets with or without immune checkpoint inhibitors.\n* Adequate organ function defined as; Absolute neutrophil count of more than 1.5×109 cells per L, more than 100×109 platelets per L, conjugated bilirubin serum concentration of up to 1.5 times the upper limit of normal, serum concentrations of alkaline phosphatase and aminotransferases of up to 2.5 times the upper limit of normal, and creatinine clearance of more than 60 mL\u002F min.\n\nExclusion Criteria:\n\n* History of hypersensitivity to alpha lipoic acid.\n* Pregnancy or lactation.\n* patients receiving medications that interact with alpha lipoic acid, such as:\n* Iron supplements\n* Thyroid medications\n* Patients with severe cognitive impairments, neurological disorders (e.g., dementia, Alzheimer's disease), or severe psychiatric conditions that would interfere with the ability to comply with study protocols or follow-up\n* Uncontrolled heart disease (e.g., recent myocardial infarction, congestive heart failure)\n* Severe hypertension not controlled by medication\n* Patients with brain metastases.",{"count":112,"type":21},60,[24],"Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer often diagnosed at advanced stages, with limited treatment options and poor prognosis. Oxidative stress, inflammation, and dysregulated signaling pathways contribute to tumor progression, metastasis, and chemotherapy resistance. Alpha-lipoic acid (ALA), a potent antioxidant with anti-inflammatory properties, has shown promise in preclinical and early clinical studies by reducing oxidative stress, enhancing chemotherapy efficacy, and improving immune response. The aim of this study is to evaluate the clinical effect and safety of oral ALA (600 mg daily) in combination with standard platinum-based chemotherapy in patients with advanced non-resectable Stage III or IV NSCLC. Primary outcomes include clinical benefit and tumor response, while secondary outcomes include 1-year progression-free survival, 1-year overall survival, chemotherapy toxicity, and quality of life.",[27],[117,118,119,120,121],"Non small cell lung cancer","neuron specific enolase","alpha lipoic acid","survival","progression","2026-05-05",{"date":124,"type":32},"2026-05-08",{"date":126,"type":21},"2026-04-20",{"date":128,"type":21},"2027-04-20",{"name":130,"class":79},"Ain Shams University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":40},"100612872","phase-2-optimal-methods-to-characterize-adc-resistance-in-solid-tumors-and-identify-clinically-useful-biomarkers-100612872","NCT07259226","Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","International Multicenter Multicohort Open-label Phase II Trial Aiming to Define Optimal Methods for Predicting Response\u002FResistance to Antibody-drug Conjugates in Patients With Solid Tumors Treated According to Current Standard Indications.","OASIS","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent form prior to any trial specific procedures;\n2. Patients must be ≥18 years old;\n3. Histologically confirmed or radiologically documented unresectable locally advanced or metastatic cancer (Breast, Urothelial, Non small Cell Lung or Gastric) with an indication to receive an Antibody-Drug Conjugate (ADC) approved or accessible through an early access program;\n4. Patients must have at least 2 tumor lesions (primary tumor can be included): at least one measurable tumor lesion for tumor evaluation according to response evaluation criteria in solid tumors (RECIST) V1.1 and at least one tumor lesion other than bone and brain for biopsy;\n5. Patients must have a metastatic or locally advanced tumor site easily accessible to biopsy (with exception of bone and brain metastasis) and must have agreed to perform pretreatment and post-treatment biopsies; an archival pre-treatment biopsy may be used if it was collected within one month of enrolment, if no anticancer therapy was administered after the biopsy and if sufficient material is available for research;\n6. Life expectancy must be ≥12 weeks according to the discretion of the investigator;\n7. ECOG performance status ≤ 2;\n8. Patients must have adequate hematologic and organ function, compatible with ADC administration, as per drug-specific recommendations;\n9. Women of childbearing potential and male patient must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment for women and up to 4 months for men;\n10. Patients must be affiliated to a social security system (or equivalent);\n11. Patients must be willing and able to comply with the protocol for the duration of the trial;\n12. Patients must consent to the use of their collected tumor specimen, as well as, blood samples as detailed in the protocol for future scientific research, which includes but is not limited to DNA, RNA, and protein-based biomarker analysis.\n\nExclusion Criteria:\n\n1. Patients treated with an antibody drug conjugate in a curative setting;\n2. Patients who did not consent to sample use;\n3. Presence of another progressive pathology with short-term life-threatening prognosis;\n4. Patients undergoing concurrent treatment for a malignancy or hematologic disorder distinct from the indication for which the ADC is being administered.\n5. Patients with inadequate washout period prior to Cycle 1 Day 1, defined as:\n\n   * Whole brain radiation therapy \\\u003C14 days or stereotactic brain radiation therapy \\\u003C7 days.\n   * Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) (including another ADC) from a previous cancer treatment regimen or clinical study (other than epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), \\\u003C14 days or 5 half-lives, whichever is longer.\n   * Immune checkpoint inhibitor therapy \\\u003C21 days.\n   * Hormonal therapy \\\u003C21 days.\n   * Major surgery (excluding placement of vascular access) \\\u003C28 days.\n   * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \\\u003C28 days or palliative radiation therapy \\\u003C14 days.\n6. Female participant who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days after the final administration of study treatment;\n7. Person deprived of their liberty or under protective custody or guardianship.",{"count":140,"type":21},400,[24],"International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.",[144,145,146,27],"Advanced Breast Cancer","Advanced Gastric Cancer","Advanced Urothelial Cancer",[148,149],"ADC","resistance","2025-11-20",{"date":152,"type":32},"2025-12-02",{"date":154,"type":32},"2025-11-14",{"date":156,"type":21},"2030-11-01",{"name":158,"class":79},"UNICANCER",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100607551","phase-1-immunodynamics-guided-optimization-of-individualized-immunochemotherapy-in-advanced-driver-negative-nsclc-a-randomized-trial-100607551","NCT07190027","Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","Prospective Randomized Controlled Trial of Immunodynamics-Guided Optimization of Individualized Immunochemotherapy Infusion Timing in Driver Gene-Negative Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\nVoluntarily agree to participate, sign the informed consent form (ICF), and be able to comply with the study procedures.\n\nAge ≥18 years and ≤75 years at enrollment, both male and female participants are eligible.\n\nHistologically or cytologically confirmed stage IV non-small cell lung cancer (NSCLC) based on the AJCC 8th edition; if mixed histology exists, classification must be based on the predominant histologic component. Presence of small-cell histology excludes eligibility.\n\nNegative for actionable driver mutations: no EGFR mutations, ALK rearrangements, or ROS1 fusions. For other targetable alterations (e.g., BRAF V600E, NTRK1\u002F2\u002F3 fusions, MET exon 14 skipping, RET rearrangements), patients are excluded if FDA- or NMPA-approved targeted therapies are available.\n\nNote: Genetic testing can be conducted locally or via a central laboratory. Pre-existing valid reports are acceptable.\n\nEstimated life expectancy ≥3 months. At least one measurable lesion per RECIST v1.1 confirmed by IRC; irradiated lesions are not considered measurable unless unequivocal progression is demonstrated.\n\nECOG performance status of 0 or 1. No prior systemic therapy for advanced\u002Fmetastatic NSCLC, except adjuvant or neoadjuvant chemotherapy if the last dose was ≥6 months before recurrence.\n\nAdequate organ and bone marrow function within 14 days prior to randomization:\n\nANC ≥ 1.5 × 10⁹\u002FL Platelets ≥ 100 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula) Total bilirubin ≤ 1.5 × ULN (≤3 × ULN for Gilbert's syndrome) AST\u002FALT ≤ 2.5 × ULN (≤5 × ULN if liver metastases) INR and APTT ≤ 1.5 × ULN unless on therapeutic anticoagulation LVEF ≥ 50% by echocardiography or MUGA Female patients of childbearing potential must test negative for pregnancy within 14 days before enrollment and agree to use effective contraception from ICF signing until 180 days after the last dose. Male participants must also agree to effective contraception during the same period.\n\nExclusion Criteria:\n\nParticipants meeting any of the following are excluded:\n\nPrior thoracic radiotherapy \\>30 Gy within 6 months before first dose. Palliative radiotherapy within 7 days before first dose. Requirement for concurrent anti-tumor therapy during the study. Uncontrolled or symptomatic pleural, pericardial, or peritoneal effusions requiring repeated drainage.\n\nBrainstem, leptomeningeal, spinal cord metastases, or cord compression.\n\nActive CNS metastases or carcinomatous meningitis. Treated, stable brain metastases are allowed if:\n\nClinically stable ≥2 weeks, No evidence of progression, Off corticosteroids ≥3 days prior to treatment initiation. Previous treatment with immune checkpoint inhibitors (PD-1\u002FPD-L1, CTLA-4, etc.), immune agonists, or cellular immunotherapies.\n\nUse of traditional Chinese medicines or immunomodulatory drugs with anti-cancer activity within 2 weeks before first dose.\n\nSystemic corticosteroids (\\>10 mg prednisone equivalent\u002Fday) or other immunosuppressants within 2 weeks prior to first dose.\n\nUncontrolled systemic infection, unexplained fever \\>38.5°C, or IV antibiotic use \\>7 days within 2 weeks prior to first dose.\n\nHistory of other malignancies within the past 5 years, except adequately treated cervical carcinoma in situ, basal\u002Fsquamous cell skin cancer, localized thyroid papillary carcinoma, prostate cancer in remission, or DCIS after curative surgery.\n\nActive or history of autoimmune disease, including but not limited to: autoimmune hepatitis, interstitial lung disease, uveitis, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, or hypothyroidism.\n\nControlled hypothyroidism with hormone replacement is eligible. Vitiligo, alopecia, type 1 diabetes, resolved childhood asthma, or mild psoriasis without systemic therapy are allowed.\n\nClinically significant pulmonary diseases: e.g., steroid-requiring pneumonitis, drug-induced pneumonitis, or moderate-to-severe COPD.\n\nMajor surgery within 4 weeks prior to first dose or unresolved surgical wounds.\n\nSignificant cardiovascular diseases, including:\n\nMI, unstable angina, stroke, or TIA within 6 months Arterial thromboembolism within 6 months DVT, PE, or severe thrombosis within 3 months Uncontrolled hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg) Myocarditis or NYHA III-IV heart failure History of allogeneic HSCT or organ transplantation (except corneal).\n\n≥ Grade 2 peripheral neuropathy per CTCAE v5.0. Active tuberculosis or suspected TB not ruled out. Positive HIV antibody; active syphilis or untreated positive non-treponemal antibody; uncontrolled HBV\u002FHCV infection per protocol definition.\n\nLive vaccine administration within 30 days before first dose or planned during study.\n\nHistory of severe hypersensitivity to monoclonal antibodies, PD-1 agents, pemetrexed, carboplatin, or premedications.\n\nConcurrent participation in another interventional clinical trial or use of other investigational products\u002Fdevices within 4 weeks prior to first dose.\n\nHistory of drug\u002Falcohol abuse or uncontrolled psychiatric disorders interfering with compliance.\n\nAny other condition judged by the investigator as inappropriate for study participation.",{"count":167,"type":21},246,[90,24],"The goal of this clinical trial is to evaluate whether individualized sequencing of immunotherapy and chemotherapy based on immune dynamics can improve treatment outcomes in adults with advanced non-small cell lung cancer (NSCLC) without driver gene mutations. This study will also assess the safety and feasibility of different infusion strategies.\n\nThe main questions it aims to answer are:\n\nDoes optimizing the timing of PD-1 inhibitor infusion relative to chemotherapy improve the objective response rate (ORR)?\n\nDoes individualized infusion sequencing enhance progression-free survival (PFS) compared to standard or fixed-delay administration?\n\nWhat safety concerns or immune-related adverse events occur with different infusion timing strategies?\n\nResearchers will compare three treatment strategies:\n\nGroup A (Standard Concurrent Group): Immunotherapy and chemotherapy administered on the same day (D1).\n\nGroup B (Fixed Delay Group): Chemotherapy on D1, followed by PD-1 inhibitor infusion on Day 3.\n\nGroup C (Individualized Delay Group): Chemotherapy on D1, and PD-1 inhibitor infusion scheduled on D2-D6 based on daily immune monitoring.\n\nParticipants will:\n\nReceive a PD-1 inhibitor (e.g., sintilimab, pembrolizumab, camrelizumab) combined with platinum-based chemotherapy.\n\nAttend clinic visits for regular immune monitoring, imaging assessments, and safety checks during each treatment cycle.\n\nUndergo blood tests to evaluate immune biomarkers (e.g., CD8⁺PD-1⁺ T cells, MDSC, Treg、IFN-γ、NLR、ALC、CRP) to guide individualized treatment decisions.",[171],"Advanced Non-Small Cell Lung Cancer (NSCLC)",[173,174,175,176,177],"Non-Small Cell Lung Cancer (NSCLC)","Driver Gene-Negative NSCLC","Immunochemotherapy Sequencing","Individualized Infusion Timing","Immune Dynamics","2025-09-22",{"date":180,"type":32},"2025-09-24",{"date":182,"type":21},"2025-11",{"date":184,"type":21},"2028-11",{"name":186,"class":79},"First Affiliated Hospital of Wenzhou Medical University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100575532","phase-1-phase-i-study-of-bc008-1a-injection-in-patients-with-advanced-solid-tumors-100575532","NCT06773507","Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors","An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics and Preliminary Efficacy of BC008-1A Injection in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Cohort 1:\n\n   Patients with inoperable, locally advanced or metastatic esophageal squamous cell carcinoma confirmed by histopathology or cytology. Those who have failed standard treatment or have no effective standard treatment available; Patients can provide the results of PD-L1 expression status within 1 year or agree to provide archived pathological tissues or fresh tissues within 1 year for testing.\n\n   Cohort 2:\n\n   Patients with non-small cell lung cancer (squamous cell carcinoma and adenocarcinoma) confirmed by histology or cytology, who have failed standard treatment or have no effective standard treatment available; Patients can provide archived pathological tissues or fresh pathological tissues within 1 year for PD-L1 testing, and the PD-L1 Tumor Proportion Score (TPS) ≥ 1%.\n2. Sign a written informed consent form before any study-specific procedures and be able to follow the visit schedules and related procedures stipulated in the protocol.\n3. Male or female patients aged ≥ 18 years old.\n4. Expected survival time ≥ 12 weeks.\n5. According to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), there should be at least one measurable tumor lesion shown by CT or MRI examination (lesions that have not received radiotherapy before). If a lesion located in the irradiated area that has received radiotherapy previously clearly shows progression meeting the RECIST 1.1 criteria, such lesion can be regarded as a measurable lesion.\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status score is 0 or 1.\n7. Have sufficient hematopoietic, liver and kidney functions and meet the following laboratory test results before enrollment (no use of any cell growth factors, platelet or red blood cell transfusions, etc. within 1 week before the first dose of study treatment):\n\n   Basically normal hematopoietic system: Absolute Neutrophil Count (ANC) ≥ 1.5 × 109\u002FL, Platelet (PLT) ≥ 90 × 109\u002FL, Hemoglobin (Hb) ≥ 90 g\u002FL; Basically normal liver function: Total Bilirubin (TBIL) ≤ 1.5 × ULN (for subjects with liver metastases, Total Bilirubin ≤ 2.5 × ULN), Alanine Transaminase (ALT) ≤ 2.5 × ULN, Aspartate Transaminase (AST) ≤ 2.5 × ULN (for subjects with liver metastases, ALT ≤ 5 × ULN, AST ≤ 5 × ULN), Alkaline Phosphatase ≤ 2.5 × ULN (for subjects with liver or bone metastases, Alkaline Phosphatase ≤ 5 × ULN), Plasma Albumin (ALB) ≥ 28 g\u002FL; Basically normal kidney function: Creatinine (Cr) ≤ 1.5 × ULN, or Creatinine Clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Basically normal coagulation function: International Normalized Ratio (INR) ≤ 1.5 × ULN or Prothrombin Time (PT) ≤ 1.5 × ULN or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN (for subjects receiving anticoagulant therapy, the investigator judges that INR, PT and APTT are all within the safe and effective treatment range without clinical conditions of active bleeding or increased bleeding risk).\n8. Female subjects of childbearing age or male subjects whose partners are women of childbearing age must take effective contraceptive measures throughout the treatment period and within 6 months after the treatment period.\n\nExclusion Criteria:\n\n1. Having been previously exposed to any anti-TIGIT drugs.\n2. Currently participating in another interventional clinical study, except for participation in observational (non-interventional) clinical studies or being in the survival follow-up stage of an interventional study.\n3. Having received any investigational drugs within 4 weeks prior to the first administration of the study drug.\n4. Having an autoimmune disease or a history of autoimmune diseases or related symptoms.\n5. Having received the last anti-tumor treatment within 4 weeks before the first administration of the study drug: systemic chemotherapy (the washout period for oral fluorouracil drugs is 2 weeks, and that for mitomycin C and nitrosourea drugs is 6 weeks), endocrine therapy, targeted therapy (the washout period for small molecule targeted therapy is 2 weeks or 5 half-lives, whichever is longer), immunotherapy, tumor embolization or treatment with traditional Chinese herbal medicines with anti-tumor indications, etc.\n6. Having been treated with corticosteroid drugs or other immunosuppressive agents within 4 weeks before the first administration of the study drug.\n7. Having received a live attenuated vaccine within 4 weeks before the first administration of the study drug or planning to receive it during the study period.\n8. Having toxicity that has not recovered to grade 0 or 1 according to the NCI-CTCAE v5.0 caused by previous anti-tumor treatment within 4 weeks before the first dose of study treatment (excluding alopecia, fatigue or vitiligo), having unstable neuropathy or \\> grade 2 neuropathy induced by previous anti-tumor treatment, including having unresolved immune-related adverse events (irAE) after receiving immunotherapy and those who have experienced irAE ≥ grade 3.\n9. Having a history of pneumonia requiring steroid treatment, or having interstitial lung disease (including both past and present medical history).\n10. Currently having an active infection (e.g., acute bacterial infection, tuberculosis, active hepatitis B\u002Fhepatitis C, pulmonary infection, etc.).\n11. Known to have central nervous system (CNS) metastasis and\u002For spinal cord compression and\u002For carcinomatous meningitis, or having a history of leptomeningeal carcinoma.\n12. Being positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg), and having HBV DNA higher than the upper limit of the normal value of the study center, or being judged by the doctor to have active hepatitis, being infected with hepatitis C virus (HCV), or being positive for human immunodeficiency virus (HIV) antibody, or being positive for Treponema pallidum antibody (Tp-Ab).\n13. Having poorly controlled cardiac clinical symptoms or diseases, such as uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg), unstable angina pectoris or having had a myocardial infarction within 6 months before enrollment in the trial, or having poorly controlled arrhythmia (including QTc interval ≥ 450 ms for men and ≥ 470 ms for women, with the QTc interval calculated by the Fridericia formula), etc.\n14. Having a cardiac function classification (NYHA) of grade III or IV, and having a left ventricular ejection fraction (LVEF) \\\u003C 50% at rest.\n15. Having suffered from other malignant tumors within five years (except for completely cured or curable cancers, such as basal cell skin cancer or squamous cell skin cancer, localized low-risk prostate cancer, papillary thyroid cancer, or any type of carcinoma in situ that has been completely resected, such as carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, etc.).\n16. Being allergic to the components or excipients of the experimental drug, antibody drugs or any other therapeutic proteins (such as fresh frozen plasma, human serum albumin, cytokines or interleukins, etc.), or having a severe allergy history, or being suspected of having a severe allergic reaction (NCI-CTCAE v5.0 ≥ grade 3).\n17. Having a history of alcoholism, drug addiction or drug abuse within 1 year before screening.\n18. Having a clear history of neurological or psychiatric disorders in the past, such as epilepsy, dementia, or being poorly compliant.\n19. Pregnant or lactating women.\n20. Other circumstances that the investigator deems unsuitable for participation in this study.",{"count":195,"type":21},80,[90],"The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.",[199,54],"Advanced Esophageal Cancers",[201,202,203,204],"PD-1","TIGIT","Esophageal Cancer","non-small cell lung cancer","2025-07-07",{"date":207,"type":32},"2025-07-09",{"date":209,"type":32},"2025-05-12",{"date":211,"type":21},"2027-06",{"name":213,"class":39},"Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":40},"100572098","phase-2-efficacy-and-safety-of-vorolanib-monotherapy-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung-cancer-patients-a-single-arm-prospective-open-label-phase-ii-clinical-study-100572098","NCT06728852","Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","Vigor","Inclusion Criteria:\n\n1. Sign the informed consent\n2. Pathologically or cytologically diagnosed with metastatic\u002Frelapsed advanced NSCLC, with measurable lesions (according to RECIST 1.1)\n3. Previously received at least two systemic therapies, allowing for third-line or higher chemotherapy or unable to tolerate chemotherapy\n4. Patients with negative results for driver gene testing or patients with positive results who have already received relevant targeted drugs or systemic anti-tumor treatments and are either resistant or unable to tolerate them\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Expected survival time ≥ 3 months\n6. Normal major organ function: renal function with creatinine clearance rate ≥ 60 mL\u002Fmin; liver function with bilirubin ≤ 1.5× upper limit of normal (ULN), ALT\u002FAST ≤ 2.5× ULN (for patients with documented liver metastasis, AST and ALT levels ≤ 5× ULN)\n7. Good hematological function, defined as an absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL, platelet count ≥ 100×10\\^9\u002FL, hemoglobin ≥ 90g\u002FL (without blood transfusion or erythropoietin \\[EPO\\] dependency within the last 7 days)\n8. Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN; if the subject is on anticoagulation therapy, PT should be within the intended therapeutic range of the anticoagulant\n9. Female patients of childbearing potential must agree to use contraception (e.g., intrauterine device, contraceptives, or condoms) during the study and for 6 months after the study ends; must not be breastfeeding and must have a negative serum or urine pregnancy test within 7 days before enrollment. Male patients must agree to use contraception during the study and for 6 months after the study ends\n10. Patients with well-controlled pleural or peritoneal effusions that do not cause grade 2 or higher respiratory syndrome (≥ CTCAE grade 2) can be included\n11. Patients without clinical symptoms of intracranial hypertension caused by brain metastases or with brain metastasis symptoms that are stable after prior treatment (radiation therapy or surgery) of brain or meningeal metastasis (usually requiring more than 4 weeks post-radiation therapy)\n\nExclusion Criteria:\n\n1. Previously failed treatment with multi-target anti-angiogenic drugs, such as anlotinib, cabozantinib, apatinib, lenvatinib, etc. The use of bevacizumab is allowed, but the last administration must be more than 3 weeks before enrollment\n2. Small cell lung cancer (including small cell carcinoma, non-small cell lung cancer mixed with other types of tumors)\n3. Testing positive for driver genes but not treated with TKIs\n4. Tumor invasion of large blood vessels, central squamous cell carcinoma of the lung with cavitation, or non-small cell lung cancer with hemoptysis (\\>5ml\u002Fday), or where the tumor is likely to invade important blood vessels and cause fatal bleeding during the subsequent study period\n5. Accompanied by other types of malignant tumors within the past 5 years or currently\n6. Planning to receive systemic anti-tumor therapy within 4 weeks before enrollment or during the study period, including cytotoxic therapy, signal transduction inhibitors, and immunotherapy (or mitomycin C within 6 weeks before receiving experimental drug therapy); received extended-field radiation therapy (EF-RT) within 4 weeks before enrollment or limited-field radiation therapy within 2 weeks before enrollment with evaluation of lesions recommended\n7. Unremitting toxic reactions caused by previous treatment, CTCAE grade \\>1, excluding hair loss\n8. Various factors affecting oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea, bowel obstruction)\n9. Pleural effusion or ascites leading to respiratory syndrome (≥CTCAE grade 2)\n10. Symptoms of brain metastasis not controlled and treated within 2 months\n11. Presence of any severe or uncontrolled disease\n12. Major surgery, open biopsy, or significant traumatic injury within 28 days before enrollment\n13. Bleeding diathesis or history of significant bleeding, regardless of severity; any wound, ulcer, or fracture that has not healed following a bleeding or bleeding event (≥CTCAE grade 3)\n14. Arterial\u002Fvenous thrombosis within 6 months, such as cerebrovascular accident (including transient ischemic attack), venous thrombosis, pulmonary embolism\n15. History of substance abuse that cannot be quit or diagnosed with psychiatric disorders\n16. Participated in other clinical trials of anti-tumor drugs within 4 weeks\n17. Diagnosed with diseases that severely jeopardize patient safety or affect the completion of this study\n18. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive); untreated active hepatitis B; active HCV infection (HCV antibody positive and HCV-RNA levels above detection limit)","70 Years",{"count":223,"type":21},32,[24],"This study evaluates the efficacy and safety of Vorolanib as monotherapy for advanced non-small cell lung cancer (NSCLC) patients receiving third-line or higher treatments. It is a single-center, single-arm, prospective Phase II clinical trial. Thirty-two patients who have undergone at least two lines of systemic therapy and exhibited progression or recurrence will receive 300 mg of Vorolanib daily until disease progression, intolerable toxicity, withdrawal of consent, or death. The primary endpoint is the 6-month progression-free survival (PFS) rate. Secondary endpoints include PFS, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. This research aims to expand the clinical applications of Vorolanib in NSCLC, providing a basis for further investigation.",[54,227,228,229],"Recurrent or Metastatic Lung Cancer","Third-line and Beyond Therapy","Angiogenesis Inhibition in Oncology","2024-12-08",{"date":232,"type":32},"2024-12-11",{"date":234,"type":21},"2024-12-01",{"date":236,"type":21},"2026-12-01",{"name":238,"class":79},"Li-kun Chen"]